Vistagen Therapeutics, Inc. Gains 46.54%
Wed, Sep 23, 2026 at 07:59 PM
Vistagen Therapeutics, Inc. (VTGN:NASDAQ) rocketted at $0.37, representing a gain of 46.5%. On Wed, Sep 23, 2026, VTGN:NASDAQ hit a New 2-Week High of $0.37. The stock got featured on our News Catalysts scanner on Tue, Sep 22, 2026 at 11:08 AM in the 'BIOTECH' category. From Wed, Sep 09, 2026, the stock recorded 30.00% Up Days and 18.18% Green Days
The stock spiked on Wed, Sep 23, 2026 at $0.55 with a volume of 569M+.
About Vistagen Therapeutics, Inc. (VTGN:NASDAQ)
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
Top 10 Gainers:
- Beneficient (BENF:NASDAQ), 438.73%
- Vestand Inc Cl A (New) (VSTD:NASDAQ), 233.33%
- TCTM Kids IT Education Inc. (VSA:NASDAQ), 83.84%
- Bullfrog AI Holdings, Inc. (BFRG:NASDAQ), 58.33%
- Green Circle Decarbonize Technology Limited (GCDT:NYSEMKT), 50.03%
- Vistagen Therapeutics, Inc. (VTGN:NASDAQ), 46.54%
- Professional Diversity Network, Inc. (IPDN:NASDAQ), 38.97%
- TJGC Group Ltd Ord Shs (TJGC:NASDAQ), 37.75%
- Maison Solutions Inc. (MSS:NASDAQ), 34.62%
- Onconetix, Inc. (ONCO:NASDAQ), 32.98%